|
C13ORF38 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.60410000005218E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.5626999999574E-06 |
| Normal-vs-Stage2 |
2.663400E-03 |
| Normal-vs-Stage3 |
1.00280000003838E-06 |
| Normal-vs-Stage4 |
1.609730E-04 |
| Stage1-vs-Stage2 |
3.866000E-01 |
| Stage1-vs-Stage3 |
6.453200E-01 |
| Stage1-vs-Stage4 |
7.853000E-01 |
| Stage2-vs-Stage3 |
2.954200E-01 |
| Stage2-vs-Stage4 |
5.985400E-01 |
| Stage3-vs-Stage4 |
6.114400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.32060000002099E-06 |
| Normal-vs-AfricanAmerican |
4.06349999981792E-07 |
| Normal-vs-Asian |
2.556800E-04 |
| Caucasian-vs-AfricanAmerican |
1.827450E-01 |
| Caucasian-vs-Asian |
5.180200E-01 |
| AfricanAmerican-vs-Asian |
1.275190E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.7660000000429E-06 |
| Normal-vs-Female |
2.02189999998215E-06 |
| Male-vs-Female |
8.263000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.72249999999641E-06 |
| Normal-vs-Age(41-60Yrs) |
1.22639999999841E-06 |
| Normal-vs-Age(61-80Yrs) |
6.21259999999957E-05 |
| Normal-vs-Age(81-100Yrs) |
3.495500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.928800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.812200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.635000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.693200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.356200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.133000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.795600E-01 |
| Classical-VS-Follicular |
2.615600E-01 |
| Classical-VS-Other |
9.075400E-01 |
| Classical-VS-Normal |
1.34669999996007E-06 |
| Tall-VS-Follicular |
4.715600E-01 |
| Tall-VS-Other |
9.767600E-01 |
| Tall-VS-Normal |
1.86654999999591E-05 |
| Follicular-VS-Other |
6.495600E-01 |
| Follicular-VS-Normal |
1.599150E-04 |
| Other-VS-Normal |
1.215850E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.71210000005284E-06 |
| Normal-vs-N1 |
2.27599999998995E-05 |
| N0-vs-N1 |
9.436000E-01 |
|
|
